Francisco, Angeli .
HRN: 23-03-78 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/27/2023
CO-AMOXICLAV 625MG (TAB)
05/27/2023
06/02/2023
PO
625mg
BID
Post Episiorhaphy
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes